Märkische Allgemeine reports on CRP apheresis
23.09.2021
An article from the 'Märkische Allgemeine' reports on companies from Brandenburg, which develop therapeutics and diagnostics for COVID-19.
Therapeutic Success with novel blood washing therapy - Interview with Dr. Ahmed Sheriff
Hennigsdorf, August 2021 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin, publishes an interview with CEO Dr. Ahmed Sheriff.
The innovative and cutting-edge therapy CRP apheresis convinces.
Avoiding serious tissue damage in myocardial infarction and preserving cardiac output. A clinical study on CRP apheresis after myocardial infarction showed significantly positive results. Other cases in clinical practice support these results. Similarly, 9 Covid-19 patients - one before and the others in intensive care - have recovered. The majority were already on artificial ventilation. Unfortunately, about 50 percent of these patients die under normal conditions when treated according to guidelines.
Pentracor becomes a member of BVMed
10.08.2021
Pentracor recently joined the BVMed business association, which represents the interests of the German medtech industry and, in particular, medtech SMEs. BVMed represents around 220 industrial and commercial companies in the medical technology sector. Among others, the world's 20 largest medical device manufacturers in the consumer goods sector are organized in BVMed.
Another Case Report on CRP apheresis in COVID-19 published.
02.08.2021
Recently a new case report has been published in Frontiers in Immunology about the first COVID-19 patient at the onset of a severe COVID-19 course. Small heads-up: it turned out amazingly well!
New Case Report on a young COVID-19 patient published
27.07.2021
Another case report has been published on the successful treatment of a young, ventilated COVID-19 patient in Immenstadt. One very effective CRP apheresis was sufficient. Afterwards, the patient's clinical parameters were back to normal.
Pentracor GmbH publishes 2020 financial statements and makes good progress in the first half of 2021
Hennigsdorf, July 28, 2021 - The medical technology company Pentracor GmbH, based in Hennigsdorf near Berlin has published its 2020 annual financial statements. The financial year was characterized by the roll-out of the PentraSorb® CRP medical product developed and certified by the company, as well as the initiation and execution of clinical studies to increase acceptance for CRP apheresis in the treatment of diseases associated with acute inflammation such as myocardial infarction.
Article about the CAMI-1 study published in "Intensiv-News"
12.07.2021
In the 3rd issue of "Intensiv-News" 2021, the most recent publications on CRP apheresis were summarized and evaluated with a focus on the recently published CAMI-1 study.
Pentracor nominated for the "Zukunftspreis Brandenburg" 2021
Twelve companies have been nominated by the main jury for the "Zukunftspreis Brandenburg" 2021. Six prize winners and one company as a special prize winner will be awarded Brandenburg's most important business prize in the final on November 12 at the Airport Center Berlin Schönefeld. Pentracor GmbH, based in Hennigsdorf, is among the nominees. "We are very honored by the nomination," said Pentracor CEO Dr. Ahmed Sheriff.
Interview with Dr. Ahmed Sheriff on CRP apheresis for COVID-19 patients
08.06.2021
ntv has broadcast an interview with Dr. Ahmed Sheriff about CRP apheresis for COVID-19 patients. Among other things, they talk about the lack of funding for medical devices in the Corona Pandemic.
"Neutron" podcast presents CRP apheresis
21.05.2021
On the Neutron podcast, CRP apheresis was introduced and explained, and Dr. Ahmed Sheriff was interviewed. The focus was on the use of the therapy in COVID-19 patients.
